FluvalAB

FluvalAB is a seasonal trivalent, inactivated whole-virion influenza vaccine developed and manufactured by Omninvest Ltd. in Hungary. The vaccine is adjuvanted with aluminum phosphate and contains inactivated whole influenza virus particles, with a standard formulation of 15 µg of hemagglutinin (HA) per virus strain. Unlike split-virion or subunit vaccines, FluvalAB utilizes the entire inactivated virus to confer protection against influenza virus infection by stimulating the immune system's response to surface antigens, particularly hemagglutinin. First authorized in Hungary in 1995, it has been used in over 16 million vaccinations and has consistently met European Medicines Agency (EMEA) requirements for interpandemic influenza vaccines. Clinical evaluations, including Phase 4 serologic studies, have demonstrated its immunogenicity in healthy adults.

Brand names

FluvalABFluval AB

Other names

trivalent inactivated whole-virion influenza vaccineFluvalAB influenza vaccine